Trial Profile
Phase I Trial of Afatinib in Combination With 3 Weekly Trastuzumab in Patients With Tumours Overexpressing HER2. Once the MTD of Afatinib With 3 Weekly Trastuzumab Was Established the Safety of This Dose Will be Assessed Also in Combination With Weekly Trastuzumab
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Gastric cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 28 Jun 2016 Status changed from active, no longer recruiting to completed.
- 11 May 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016.
- 11 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jul 2016.